December 2016 Vol 7, No 11

Ms Shockney talks about the momentum of the navigation movement, accomplishments in 2016, and the expansion of JONS and AONN+ in 2017.
JONS talks to navigators Trish Leighton, Stephanie Hoopes, and Jo Weathers about their team-driven approach to patient care.
The authors present their findings from a patient satisfaction study conducted 1 year after the establishment of an oncology nurse navigation program to collect patient feedback and discover opportunities for improvements.
The authors present findings on the secondary aim of the Adherence, Communication, Treatment, and Support (ACTS) randomized controlled intervention study – a one-time psychoeducational intervention encouraging adherence of African American women to prescribed chemotherapy.
A report from the Association of Community Cancer Centers encouraging spiritual care plans for patients.
The addition of the selective CDK4/6 inhibitor ribociclib to letrozole significantly improved progression-free survival (PFS) in hormone receptor–positive (HR+) advanced breast cancer. Compared with letrozole alone, the combination of ribociclib/letrozole improved PFS by 44%.
Here is new information pertaining to this disease site for genetic testing and practice guidelines.
The past decade has witnessed dramatic progress in the treatment of multiple myeloma (MM), which has resulted in unprecedented improvements in survival outcomes.

Results 1 - 8 of 8

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code